Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

July 29, 2022 updated by: Novartis Pharmaceuticals

A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy With Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/Neu Positive Metastatic Breast Cancer

RATIONALE: HER2/neu is a receptor (protein) which is found in unusually high amounts in approximately 1 in 5 cancer patients. Scientific evidence suggests that having high amounts of the HER2/neu receptor is important for breast cancer to grow and spread. Women with previously untreated metastatic breast cancer (breast cancer that has spread to other organs) and with high levels of the HER2/neu receptor receive as their usual treatment chemotherapy with one of the approved chemotherapy drugs paclitaxel or docetaxel (called "taxanes") together with another approved drug called "trastuzumab". Chemotherapy drugs, such as paclitaxel and docetaxel, work either by killing tumour cells or by stopping them from dividing. Trastuzumab is an antibody that is given through a vein in the arm and it works by specifically "targeting" the HER2/neu i.e. it attaches to it and "turns it off". Although some of the patients who receive this taxane plus trastuzumab treatment feel better for some months, the cancer usually starts to grow again. Lapatinib is a new drug. Like trastuzumab, it also works by specifically "targeting" the HER2/neu receptor, but it does so in a different way. Lapatinib is not an antibody. It is a pill that is taken daily by mouth. Because lapatinib works in a different way than trastuzumab, it may be worse, as good as or better than trastuzumab in keeping metastatic HER/neu positive cancer from growing. However, this is not known.

Purpose: This randomized Phase III trial is comparing chemotherapy (a taxane) given together with lapatinib with chemotherapy (a taxane) given together with trastuzumab in women with HER2/neu positive breast cancer.

Study Overview

Detailed Description

OBJECTIVES:

Primary

  • To compare the progression-free survival of women with HER2/neu-positive metastatic breast cancer treated with taxane-based chemotherapy in combination with lapatinib ditosylate or trastuzumab (Herceptin®).

Secondary

  • To compare the overall survival.
  • To compare the time to CNS metastases at the time of first progression.
  • To compare the incidence rates of CNS metastases at the time of progression.
  • To compare the overall objective response rate (complete or partial response), time to response, and duration of response in patients with measurable disease at baseline.
  • To compare the clinical benefit response rate.
  • To compare the adverse event profile.
  • To compare the quality of life.
  • To compare clinical outcomes using biomarker changes in biological samples.
  • To compare health economics, including healthcare utilization and health utilities.

OUTLINE: This is a multicenter study. Patients are stratified according to prior neoadjuvant/adjuvant anti-HER2/neu-targeted therapy (yes vs no), prior neoadjuvant/adjuvant taxane chemotherapy (yes vs no), planned taxane therapy (paclitaxel vs docetaxel), and liver metastasis (yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive either paclitaxel IV on days 1, 8, and 15; treatment with paclitaxel repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Alternatively, patients may receive docetaxel IV on day 1; treatment with docetaxel repeats every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity. Patients on docetaxel also receive filgrastim (G-CSF) according to institutional standard. All patients receive oral lapatinib ditosylate once daily during taxane treatment and continue after completion of taxane treatment, in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive paclitaxel IV on days 1, 8, and 15 and trastuzumab (Herceptin®) IV on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Alternatively, patients may receive docetaxel IV and trastuzumab IV on day 1. Treatment repeats every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity. After completion of taxane chemotherapy and trastuzumab, all patients receive trastuzumab alone IV once every 3 weeks in the absence of disease progression or unacceptable toxicity.

Formalin-fixed paraffin-embedded tissue samples are analyzed for ER, PgR, EGFR, CK5/6, Ki67, and other molecular biomarkers by tissue microarray and immunohistochemistry.

Patients complete quality of life questionnaires (EORTC QLQ-C30 and a Trial Specific Checklist) at baseline, every 12 weeks for 96 weeks, and then every 24 weeks until disease progression.

After completion of study treatment, patients are followed at 4 weeks post treatment, and then every 12 weeks thereafter (counting from the beginning of study therapy).

Study Type

Interventional

Enrollment (Actual)

652

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Santa Fe, Argentina, 3000
        • Novartis Investigative Site
      • Tucuman, Argentina, 4000
        • Novartis Investigative Site
    • Buenos Aires
      • Capital Federal, Buenos Aires, Argentina, C1426ANZ
        • Novartis Investigative Site
      • Capital Federal, Buenos Aires, Argentina, C1405CUB
        • Novartis Investigative Site
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1280AEB
        • Novartis Investigative Site
      • La Plata, Buenos Aires, Argentina, B1920CMK
        • Novartis Investigative Site
    • Río Negro
      • Cipolletti, Río Negro, Argentina, R8324EMB
        • Novartis Investigative Site
      • Viedma, Río Negro, Argentina, R8500ACE
        • Novartis Investigative Site
    • Santa Fe
      • Rosario, Santa Fe, Argentina, S2000KZE
        • Novartis Investigative Site
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australia, 2606
        • Novartis Investigative Site
    • New South Wales
      • Liverpool, New South Wales, Australia, 2170
        • Novartis Investigative Site
      • North Sydney, New South Wales, Australia, 2060
        • Novartis Investigative Site
      • Tweed Heads, New South Wales, Australia, 2485
        • Novartis Investigative Site
    • Queensland
      • Woolloongabba, Queensland, Australia, 4102
        • Novartis Investigative Site
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Novartis Investigative Site
      • Bedford Park, South Australia, Australia, 5042
        • Novartis Investigative Site
      • Kurralta Park, South Australia, Australia, 5037
        • Novartis Investigative Site
    • Tasmania
      • Hobart, Tasmania, Australia, 7000
        • Novartis Investigative Site
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • Novartis Investigative Site
      • Fitzroy, Victoria, Australia, 3065
        • Novartis Investigative Site
      • Wodonga, Victoria, Australia, 3690
        • Novartis Investigative Site
    • Western Australia
      • Subiaco, Western Australia, Australia, 6008
        • Novartis Investigative Site
      • Gent, Belgium, 9000
        • Novartis Investigative Site
      • Jette, Belgium, 1090
        • Novartis Investigative Site
      • Liege, Belgium, 4000
        • Novartis Investigative Site
      • Namur, Belgium, 5000
        • Novartis Investigative Site
      • Quebec, Canada, G1S 4L8
        • Novartis Investigative Site
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Novartis Investigative Site
    • British Columbia
      • Kelowna, British Columbia, Canada, V1Y 5L3
        • Novartis Investigative Site
      • Surrey, British Columbia, Canada, V3V 1Z2
        • Novartis Investigative Site
      • Vancouver, British Columbia, Canada, V5Z 4E6
        • Novartis Investigative Site
      • Victoria, British Columbia, Canada, V8R 6V5
        • Novartis Investigative Site
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 0V9
        • Novartis Investigative Site
    • New Brunswick
      • Moncton, New Brunswick, Canada, E1C 6Z8
        • Novartis Investigative Site
      • Saint John, New Brunswick, Canada, E2L 4L2
        • Novartis Investigative Site
    • Ontario
      • Barrie, Ontario, Canada, L4M 6M2
        • Novartis Investigative Site
      • Hamilton, Ontario, Canada, L8V 5C2
        • Novartis Investigative Site
      • Kingston, Ontario, Canada, K7L 5P9
        • Novartis Investigative Site
      • London, Ontario, Canada, N6A 4L6
        • Novartis Investigative Site
      • Newmarket, Ontario, Canada, L3Y 2P9
        • Novartis Investigative Site
      • Ottawa, Ontario, Canada, K1H 8L6
        • Novartis Investigative Site
      • Sault Ste. Marie, Ontario, Canada, P6B 0A8
        • Novartis Investigative Site
      • St Catharines, Ontario, Canada, L2R 7C6
        • Novartis Investigative Site
      • Sudbury, Ontario, Canada, P3E 5J1
        • Novartis Investigative Site
      • Thunder Bay, Ontario, Canada, P7B 6V4
        • Novartis Investigative Site
    • Prince Edward Island
      • Charlottetown, Prince Edward Island, Canada, C1A 8T5
        • Novartis Investigative Site
    • Quebec
      • Montreal, Quebec, Canada, H2W 1S6
        • Novartis Investigative Site
      • Montreal, Quebec, Canada, H1T 2M4
        • Novartis Investigative Site
      • Montreal, Quebec, Canada, H2L 4M1
        • Novartis Investigative Site
    • Saskatchewan
      • Regina, Saskatchewan, Canada, S4T 7T1
        • Novartis Investigative Site
      • Saskatoon, Saskatchewan, Canada, S7N 4H4
        • Novartis Investigative Site
      • Angers, France, 49033
        • Novartis Investigative Site
      • Bordeaux, France, 33075
        • Novartis Investigative Site
      • Bordeaux, France, 33077
        • Novartis Investigative Site
      • Caen Cedex 05, France, 14076
        • Novartis Investigative Site
      • Marseille cedex 9, France, 13273
        • Novartis Investigative Site
      • Metz-Tessy, France, 74370
        • Novartis Investigative Site
      • Nantes cedex, France, 44202
        • Novartis Investigative Site
      • Paris, France, 75014
        • Novartis Investigative Site
      • Strasbourg, France, 67085
        • Novartis Investigative Site
      • Berlin, Germany, 10117
        • Novartis Investigative Site
      • Berlin, Germany, 10367
        • Novartis Investigative Site
      • Brandenburg, Germany, 14770
        • Novartis Investigative Site
      • Hamburg, Germany, 22081
        • Novartis Investigative Site
      • Hamburg, Germany, 20095
        • Novartis Investigative Site
      • Hamburg, Germany, 22767
        • Novartis Investigative Site
    • Baden-Wuerttemberg
      • Heidelberg, Baden-Wuerttemberg, Germany, 69115
        • Novartis Investigative Site
      • Stuttgart, Baden-Wuerttemberg, Germany, 70190
        • Novartis Investigative Site
    • Bayern
      • Coburg, Bayern, Germany, 96450
        • Novartis Investigative Site
      • Eggenfelden, Bayern, Germany, 84307
        • Novartis Investigative Site
      • Fuerth, Bayern, Germany, 90766
        • Novartis Investigative Site
      • Regensburg, Bayern, Germany, 93049
        • Novartis Investigative Site
      • Rosenheim, Bayern, Germany, 83022
        • Novartis Investigative Site
      • Weiden, Bayern, Germany, 92637
        • Novartis Investigative Site
    • Brandenburg
      • Fuerstenwalde, Brandenburg, Germany, 15517
        • Novartis Investigative Site
    • Hessen
      • Frankfurt, Hessen, Germany, 60596
        • Novartis Investigative Site
      • Fulda, Hessen, Germany, 36043
        • Novartis Investigative Site
      • Lich, Hessen, Germany, 35423
        • Novartis Investigative Site
    • Niedersachsen
      • Goslar, Niedersachsen, Germany, 38642
        • Novartis Investigative Site
      • Hannover, Niedersachsen, Germany, 30559
        • Novartis Investigative Site
      • Leer, Niedersachsen, Germany, 26789
        • Novartis Investigative Site
    • Nordrhein-Westfalen
      • Bielefeld, Nordrhein-Westfalen, Germany, 33611
        • Novartis Investigative Site
      • Bonn, Nordrhein-Westfalen, Germany, 53113
        • Novartis Investigative Site
      • Coesfeld, Nordrhein-Westfalen, Germany, 48653
        • Novartis Investigative Site
      • Essen, Nordrhein-Westfalen, Germany, 45122
        • Novartis Investigative Site
      • Koeln, Nordrhein-Westfalen, Germany, 51067
        • Novartis Investigative Site
      • Porta Westfalica, Nordrhein-Westfalen, Germany, 32457
        • Novartis Investigative Site
      • Troisdorf, Nordrhein-Westfalen, Germany, 53840
        • Novartis Investigative Site
      • Velbert, Nordrhein-Westfalen, Germany, 42551
        • Novartis Investigative Site
      • Witten, Nordrhein-Westfalen, Germany, 58452
        • Novartis Investigative Site
    • Rheinland-Pfalz
      • Koblenz, Rheinland-Pfalz, Germany, 56068
        • Novartis Investigative Site
    • Saarland
      • Saarbruecken, Saarland, Germany, 66113
        • Novartis Investigative Site
    • Sachsen
      • Dresden, Sachsen, Germany, 01127
        • Novartis Investigative Site
    • Sachsen-Anhalt
      • Halle, Sachsen-Anhalt, Germany, 06120
        • Novartis Investigative Site
    • Schleswig-Holstein
      • Luebeck, Schleswig-Holstein, Germany, 23538
        • Novartis Investigative Site
      • Bangalore, India, 560038
        • Novartis Investigative Site
      • Nagpur, India, 440010
        • Novartis Investigative Site
      • Pune, India, 411001
        • Novartis Investigative Site
      • Beer-Sheva, Israel, 84101
        • Novartis Investigative Site
      • Holon, Israel, 58100
        • Novartis Investigative Site
      • Petah-Tikva, Israel, 49100
        • Novartis Investigative Site
      • Poriya, Israel, 15208
        • Novartis Investigative Site
      • Ramat Gan, Israel, 52621
        • Novartis Investigative Site
      • Chieti, Italy, 66100
        • Novartis Investigative Site
    • Friuli-Venezia-Giulia
      • Aviano (pn), Friuli-Venezia-Giulia, Italy, 33081
        • Novartis Investigative Site
    • Lazio
      • Roma, Lazio, Italy, 00189
        • Novartis Investigative Site
      • Sora (FR), Lazio, Italy, 03039
        • Novartis Investigative Site
    • Liguria
      • Genova, Liguria, Italy, 16132
        • Novartis Investigative Site
    • Puglia
      • Lecce, Puglia, Italy, 73100
        • Novartis Investigative Site
    • Sardegna
      • Sassari, Sardegna, Italy, 07100
        • Novartis Investigative Site
    • Toscana
      • Prato (PO), Toscana, Italy, 59100
        • Novartis Investigative Site
      • Aichi, Japan, 464-8681
        • Novartis Investigative Site
      • Chiba, Japan, 277-8577
        • Novartis Investigative Site
      • Ehime, Japan, 791-0280
        • Novartis Investigative Site
      • Kagoshima, Japan, 892-0833
        • Novartis Investigative Site
      • Kanagawa, Japan, 241-8515
        • Novartis Investigative Site
      • Osaka, Japan, 540-0006
        • Novartis Investigative Site
      • Osaka, Japan, 565-0871
        • Novartis Investigative Site
      • Saitama, Japan, 350-1298
        • Novartis Investigative Site
      • Saitama, Japan, 362-0806
        • Novartis Investigative Site
      • Shizuoka, Japan, 411-8777
        • Novartis Investigative Site
      • Tokyo, Japan, 104-8560
        • Novartis Investigative Site
      • Tokyo, Japan, 113-8677
        • Novartis Investigative Site
      • Gyeonggi-do, Korea, Republic of, 10408
        • Novartis Investigative Site
      • Gyeonggi-do, Korea, Republic of, 410-769
        • Novartis Investigative Site
      • Seoul, Korea, Republic of, 03722
        • Novartis Investigative Site
      • Seoul, Korea, Republic of, 120-752
        • Novartis Investigative Site
      • Seoul, Korea, Republic of, 110-744
        • Novartis Investigative Site
      • Songpa-gu, Seoul, Korea, Republic of, 138-736
        • Novartis Investigative Site
      • Mexico City, Mexico, CP 14080
        • Novartis Investigative Site
    • Morelos
      • Cuernavaca, Morelos, Mexico, 62450
        • Novartis Investigative Site
    • Sonora
      • Ciudad Obregon, Sonora, Mexico, 85000
        • Novartis Investigative Site
      • Amsterdam, Netherlands, 1091 AC
        • Novartis Investigative Site
      • Delft, Netherlands, 2625 AD
        • Novartis Investigative Site
      • Dordrecht, Netherlands, 3318 AT
        • Novartis Investigative Site
      • Maastricht, Netherlands, 6229 HX
        • Novartis Investigative Site
      • Gdansk, Poland, 80-219
        • Novartis Investigative Site
      • Lodz, Poland, 93-509
        • Novartis Investigative Site
      • Olsztyn, Poland, 10-226
        • Novartis Investigative Site
      • Olsztyn, Poland, 10-513
        • Novartis Investigative Site
      • Plock, Poland, 09-400
        • Novartis Investigative Site
      • Rzeszow, Poland, 35-021
        • Novartis Investigative Site
      • Warszawa, Poland, 02-781
        • Novartis Investigative Site
      • Warszawa, Poland, 04-125
        • Novartis Investigative Site
      • Arkhangelsk, Russian Federation, 163045
        • Novartis Investigative Site
      • Ivanovo, Russian Federation, 153013
        • Novartis Investigative Site
      • Kazan, Russian Federation, 420029
        • Novartis Investigative Site
      • Kirov, Russian Federation, 610021
        • Novartis Investigative Site
      • Lipetsk, Russian Federation, 398005
        • Novartis Investigative Site
      • Moscow, Russian Federation, 115 478
        • Novartis Investigative Site
      • Ryazan, Russian Federation, 390011
        • Novartis Investigative Site
      • St. Petersburg, Russian Federation, 197758
        • Novartis Investigative Site
      • St. Petersburg, Russian Federation, 197022
        • Novartis Investigative Site
      • Stavropol, Russian Federation, 355047
        • Novartis Investigative Site
      • Ufa, Russian Federation, 450054
        • Novartis Investigative Site
      • Ufa,, Russian Federation, 450054
        • Novartis Investigative Site
      • Alcorcon, Spain, 28922
        • Novartis Investigative Site
      • Alicante, Spain, 03010
        • Novartis Investigative Site
      • Badalona, Spain, 08916
        • Novartis Investigative Site
      • Barcelona, Spain, 08036
        • Novartis Investigative Site
      • Elche, Spain, 03202
        • Novartis Investigative Site
      • Girona, Spain, 17007
        • Novartis Investigative Site
      • Jaen, Spain, 23007
        • Novartis Investigative Site
      • La Coruna, Spain, 15009
        • Novartis Investigative Site
      • Lugo, Spain, 27003
        • Novartis Investigative Site
      • Madrid, Spain, 28034
        • Novartis Investigative Site
      • Madrid, Spain, 28007
        • Novartis Investigative Site
      • Madrid, Spain, 28040
        • Novartis Investigative Site
      • Majadahonda (Madrid), Spain, 28222
        • Novartis Investigative Site
      • Pozuelo De Alarcon (Madrid), Spain, 28223
        • Novartis Investigative Site
      • Sevilla, Spain, 41013
        • Novartis Investigative Site
      • Valencia, Spain, 46009
        • Novartis Investigative Site
      • Changhua, Taiwan, 500
        • Novartis Investigative Site
      • Taichung, Taiwan, 404
        • Novartis Investigative Site
      • Tainan County, Taiwan, 736
        • Novartis Investigative Site
      • Taipei, Taiwan, 100
        • Novartis Investigative Site
      • Taipei, Taiwan, 112
        • Novartis Investigative Site
      • Bangkok, Thailand, 10700
        • Novartis Investigative Site
      • Chiangmai, Thailand, 50200
        • Novartis Investigative Site
      • Dnepropetrovsk, Ukraine, 49102
        • Novartis Investigative Site
      • Dnipropetrovsk, Ukraine, 49100
        • Novartis Investigative Site
      • Lviv, Ukraine, 79031
        • Novartis Investigative Site
      • Sumy, Ukraine, 40005
        • Novartis Investigative Site
      • Bournemouth, United Kingdom, BH7 7DW
        • Novartis Investigative Site
      • Brighton, United Kingdom, BN2 5BE
        • Novartis Investigative Site
      • Chelmsford, United Kingdom, CM1 7ET
        • Novartis Investigative Site
      • Cheltenham, United Kingdom, GL53 7AN
        • Novartis Investigative Site
      • Colchester, United Kingdom, CO3 3NB
        • Novartis Investigative Site
      • Cottingham, Hull, United Kingdom, HU16 5JQ
        • Novartis Investigative Site
      • Derby, United Kingdom, DE22 3NE
        • Novartis Investigative Site
      • Edmonton, United Kingdom, N18 1QX
        • Novartis Investigative Site
      • Guildford, United Kingdom, GU2 7XX
        • Novartis Investigative Site
      • Harrogate, United Kingdom, HG2 7SX
        • Novartis Investigative Site
      • Huddersfield, United Kingdom, HD3 3EA
        • Novartis Investigative Site
      • London, United Kingdom, SW3 6JJ
        • Novartis Investigative Site
      • Newcastle upon Tyne, United Kingdom, NE7 7DN
        • Novartis Investigative Site
      • Norwich, United Kingdom, NR4 7UY
        • Novartis Investigative Site
      • Nottingham, United Kingdom, NG5 1PB
        • Novartis Investigative Site
      • Oxford, United Kingdom, OX3 7LJ
        • Novartis Investigative Site
      • Poole, Dorset, United Kingdom, BH15 2JB
        • Novartis Investigative Site
      • Sheffield, United Kingdom, S10 2SJ
        • Novartis Investigative Site
      • Shrewsbury, United Kingdom, SY3 8XQ
        • Novartis Investigative Site
      • Sutton, United Kingdom, SM2 5PT
        • Novartis Investigative Site
      • Whitchurch, Cardiff, United Kingdom, CF14 2TL
        • Novartis Investigative Site
      • York, United Kingdom, YO31 8HE
        • Novartis Investigative Site
    • Alaska
      • Anchorage, Alaska, United States, 99508
        • Novartis Investigative Site
    • Arizona
      • Tucson, Arizona, United States, 85715
        • Novartis Investigative Site
    • Arkansas
      • Hot Springs, Arkansas, United States, 71913
        • Novartis Investigative Site
    • California
      • Berkeley, California, United States, 94704
        • Novartis Investigative Site
      • Highland, California, United States, 92346
        • Novartis Investigative Site
      • Montebello, California, United States, 90640
        • Novartis Investigative Site
    • Colorado
      • Colorado Springs, Colorado, United States, 80907
        • Novartis Investigative Site
      • Denver, Colorado, United States, 80204
        • Novartis Investigative Site
    • Connecticut
      • Greenwich, Connecticut, United States, 06830
        • Novartis Investigative Site
      • Southington, Connecticut, United States, 06489
        • Novartis Investigative Site
      • Stamford, Connecticut, United States, 06902-3628
        • Novartis Investigative Site
      • Trumbull, Connecticut, United States, 06611
        • Novartis Investigative Site
      • Waterbury, Connecticut, United States, 06708
        • Novartis Investigative Site
    • Florida
      • Kissimmee, Florida, United States, 34741
        • Novartis Investigative Site
      • Loxahatchee Groves, Florida, United States, 33470
        • Novartis Investigative Site
      • New Port Richey, Florida, United States, 34655
        • Novartis Investigative Site
    • Georgia
      • Augusta, Georgia, United States, 30901
        • Novartis Investigative Site
      • Lawrenceville, Georgia, United States, 30046
        • Novartis Investigative Site
      • Savannah, Georgia, United States, 31405
        • Novartis Investigative Site
    • Idaho
      • Post Falls, Idaho, United States, 83854
        • Novartis Investigative Site
    • Illinois
      • Chicago, Illinois, United States, 60657
        • Novartis Investigative Site
      • Oak Lawn, Illinois, United States, 60453
        • Novartis Investigative Site
    • Indiana
      • Evansville, Indiana, United States, 47713
        • Novartis Investigative Site
      • Goshen, Indiana, United States, 46526
        • Novartis Investigative Site
      • Indianapolis, Indiana, United States, 46237
        • Novartis Investigative Site
      • Munster, Indiana, United States, 46321
        • Novartis Investigative Site
      • New Albany, Indiana, United States, 47150
        • Novartis Investigative Site
    • Maryland
      • Towson, Maryland, United States, 21204
        • Novartis Investigative Site
      • Wheaton, Maryland, United States, 20902
        • Novartis Investigative Site
    • Montana
      • Bozeman, Montana, United States, 59715
        • Novartis Investigative Site
    • Nebraska
      • Grand Island, Nebraska, United States, 68803
        • Novartis Investigative Site
      • Kearney, Nebraska, United States, 68845
        • Novartis Investigative Site
      • Kearney, Nebraska, United States, 68847
        • Novartis Investigative Site
    • New Jersey
      • Denville, New Jersey, United States, 07834
        • Novartis Investigative Site
      • Parsippany, New Jersey, United States, 07054
        • Novartis Investigative Site
    • New York
      • Cooperstown, New York, United States, 13326
        • Novartis Investigative Site
    • North Carolina
      • Greensboro, North Carolina, United States, 27403
        • Novartis Investigative Site
    • Ohio
      • Canton, Ohio, United States, 44718
        • Novartis Investigative Site
      • Wooster, Ohio, United States, 44691
        • Novartis Investigative Site
    • Oregon
      • Portland, Oregon, United States, 97227
        • Novartis Investigative Site
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15212-4772
        • Novartis Investigative Site
    • South Carolina
      • Columbia, South Carolina, United States, 29210
        • Novartis Investigative Site
    • Tennessee
      • Memphis, Tennessee, United States, 38120
        • Novartis Investigative Site
    • Virginia
      • Chesapeake, Virginia, United States, 23320
        • Novartis Investigative Site
      • Salem, Virginia, United States, 24153
        • Novartis Investigative Site
    • Washington
      • Bellevue, Washington, United States, 98004
        • Novartis Investigative Site
      • Kirkland, Washington, United States, 98034
        • Novartis Investigative Site
      • Mount Vernon, Washington, United States, 98273
        • Novartis Investigative Site
      • Seattle, Washington, United States, 98109
        • Novartis Investigative Site
      • Sequim, Washington, United States, 98382
        • Novartis Investigative Site
      • Tacoma, Washington, United States, 98405
        • Novartis Investigative Site
      • Wenatchee, Washington, United States, 98801
        • Novartis Investigative Site
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53226
        • Novartis Investigative Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

DISEASE CHARACTERISTICS:

  • Histologically confirmed adenocarcinoma of the breast
  • Metastatic (stage IV) disease at primary diagnosis or at relapse after curative intent therapy
  • Local or central laboratory confirmedHER2/neu* overexpressing and/or amplified disease in the invasive component of the primary or metastatic lesion as defined by the following:

    • 3+ overexpression (in > 30% of invasive tumor cells) by immunohistochemistry (IHC)
    • 2+ or 3+ overexpression (in ≤ 30% of invasive tumor cells) by IHC AND demonstrates HER2/neu gene amplification by fluorescence in situ hybridization (FISH) or chromogenic in situ hybridization (CISH)
    • HER2/neu gene amplification by FISH/CISH (> 6 HER2/neu gene copies per nucleus, or a FISH/CISH ratio [HER2 gene copies to chromosome 17 signals] of ≥ 2.2) NOTE: *Patients with a negative or equivocal overall result (FISH/CISH ratio of < 2.2, ≤ 6.0 HER2/neu gene copies per nucleus, or staining scores of 0, 1+, 2+, or 3+ [in ≤ 30% of neoplastic cells] by IHC) are not eligible
  • Formalin-fixed paraffin-embedded tumor specimen available
  • No CNS metastases (including leptomeningeal involvement)
  • Hormone receptor status not specified

PATIENT CHARACTERISTICS:

  • Menopausal status not specified
  • ECOG performance status 0-2
  • Life expectancy > 6 months
  • Absolute granulocyte count > 1,500/mm³
  • Platelet count > 75,000/mm³
  • Hemoglobin > 10 g/dL
  • Serum creatinine ≤ 2.0 times upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 times ULN (< 3 times ULN for patients with Gilbert's disease)
  • AST and/or ALT ≤ 2.5 times ULN (< 5 times ULN for patients planning to receive paclitaxel-based therapy)
  • LVEF ≥ 50% by MUGA or ECHO
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Must be accessible for study treatment and follow-up
  • No history of other malignancies, except adequately treated ductal carcinoma in situ or lobular carcinoma in situ, adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other curatively treated solid tumor (non-breast) with no evidence of disease for ≥ 5 years
  • No serious cardiac illness or condition including, but not limited to, any of the following:

    • History of documented congestive heart failure
    • Systolic dysfunction (LVEF < 50%)
    • High-risk uncontrolled arrhythmias (i.e., ventricular tachycardia, high-grade atrioventricular block, or supraventricular arrhythmias that are not adequately rate-controlled)
    • Unstable angina pectoris requiring anti-anginal medication
    • Clinically significant valvular heart disease
    • Evidence of transmural infarction on ECG
    • Inadequately controlled hypertension (i.e., systolic blood pressure [BP] > 180 mm Hg or diastolic BP > 100 mm Hg)
    • New York Heart Association class III-IV functional status
  • No serious illness or medical condition that would not allow the patient to be managed according to the protocol including, but not limited to, any of the following:

    • History of significant neurologic or psychiatric disorder that would impair the ability to obtain informed consent or limit compliance with study requirements
    • Active uncontrolled infection
    • Serious or nonhealing wound, ulcer, or bone fracture
  • No peripheral neuropathy ≥ grade 2
  • No gastrointestinal (GI) tract disease resulting in an inability to take oral medication including, but not limited to, any of the following:

    • Malabsorption syndrome
    • Requirement for IV alimentation
    • Uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)
  • No history of allergic or hypersensitivity reactions to any study drug or their excipients or to compounds with similar chemical composition to any of the study drugs

    • Prior allergic reactions to taxanes are allowed provided they were adequately treated and, according to the treating physician, would not prohibit further treatment with taxanes

PRIOR CONCURRENT THERAPY:

  • Recovered from all prior therapy
  • No prior chemotherapy, immunotherapy, biological therapy, or anti-HER2/neu-targeted therapy for recurrent or metastatic breast cancer
  • At least 12 months since prior chemotherapeutic agents, including taxanes, in the neoadjuvant or adjuvant setting
  • At least 12 months since prior anti-HER2/neu-targeted therapy in the neoadjuvant or adjuvant setting
  • Prior treatment with endocrine therapy in the neoadjuvant, adjuvant, or metastatic setting allowed
  • At least 2 weeks since prior radiotherapy in the adjuvant or metastatic setting

    • Prior radiotherapy to a solitary metastatic lesion allowed provided there is documented disease progression after completion of radiotherapy
  • More than 30 days (or 5 half-lives) since prior investigational drugs
  • At least 7 days since prior and no concurrent CYP3A4 inhibitors (6 months for amiodarone)
  • At least 14 days since prior and no concurrent CYP3A4 inducers
  • No prior surgical procedures affecting absorption (e.g., resection of stomach or small bowel)
  • No concurrent palliative radiotherapy
  • No other concurrent anticancer treatment
  • No other concurrent investigational drugs for breast cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Lapatinib
Plus taxane based chemotherapy
75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
1250 mg po daily (while given with taxane). 1500mg PO daily (when given alone after taxane completion).
80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
Active Comparator: Trastuzumab
Plus taxane based chemotherapy.
75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression-free Survival
Time Frame: From randomization to RECIST V 1.0 progression or death assessed up to 39 months.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
From randomization to RECIST V 1.0 progression or death assessed up to 39 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Survival
Time Frame: From randomization to death from any cause, assessed up to 44 months.
OS median follow-up not achieved; estimated with quartile estimates
From randomization to death from any cause, assessed up to 44 months.
Time to CNS Metastases at the Time of First Progression
Time Frame: From randomization to CNS metastases at time of first progression, assessed up to 39 months.
From randomization to CNS metastases at time of first progression, assessed up to 39 months.
CNS Metastases at the Time of Progression (ITT)
Time Frame: Incidence rate of CNS metastases at first progression assessed up to 39 months
Incidence rate of CNS metastases at first progression assessed up to 39 months
CNS Metastases at the Time of Progression (HER2+)
Time Frame: Incidence rate of CNS mestastes at first progression, assessed up to 39 months
Incidence rate of CNS mestastes at first progression, assessed up to 39 months
Overall Objective Response Rate (Complete or Partial) ITT
Time Frame: 4 years
Patients included in this assessment must have had at least one measurable lesion at baseline, and had at least one RECIST re-evaluation after baseline while on protocol therapy, prior to, or on, date of progression. Best overall response was classified to be Complete Response (CR) or Partial Response (PR).
4 years
Overall Objective Response Rate (Complete or Partial) HER2/Neu+
Time Frame: Median follow-up of 21.5 months.
Response determined by RECIST V 1.0
Median follow-up of 21.5 months.
Clinical Benefit Response Rate (ITT)
Time Frame: 24 weeks
Best overall response of CR, PR or stable disease at end of week 24.
24 weeks
Clinical Benefit Response Rate (HER2/Neu+))
Time Frame: 24 weeks
Best overall response of CR, PR, or stable disease at end of week 24.
24 weeks
Quality of Life as Measured by the EORTC QLQ-C30 Global Score From Baseline to 12 Weeks
Time Frame: 12 weeks
The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. The global score ranges from 0-100, with higher values representing a better quality of life. At 12 weeks: Group mean difference between arms
12 weeks
Effects of Changes in Biomarkers on Clinical Outcomes
Time Frame: Not available at this time
Not available at this time
Economic Evaluation, Including Health Utilities, as Measured by the EQ-5D Questionnaire, and Healthcare Utilization
Time Frame: Not available at this time
Not available at this time

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 7, 2008

Primary Completion (Actual)

August 1, 2012

Study Completion (Actual)

July 27, 2022

Study Registration Dates

First Submitted

April 25, 2008

First Submitted That Met QC Criteria

April 25, 2008

First Posted (Estimate)

April 28, 2008

Study Record Updates

Last Update Posted (Actual)

August 2, 2022

Last Update Submitted That Met QC Criteria

July 29, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 108919
  • CLAP016A2303 (Other Identifier: Novartis)
  • CAN-NCIC-MA31 (Other Grant/Funding Number: NCI US - Physician Data Query)
  • 2007-004568-27 (EudraCT Number)
  • CDR0000594764 (Other Identifier: PDQ)
  • EGF108919 (Other Identifier: GSK)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on docetaxel

3
Subscribe